Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection

著者: Randy M. Stalter, Jared M. Baeten, Deborah Donnell, Matthew A. Spinelli, David V. Glidden, Warren C. Rodrigues, Guohong Wang, Michael S. Vincent, Nelly Mugo, Andrew Mujugira, Mark A. Marzinke, Craig W. Hendrix, Monica Gandhi, for the Partners PrEP Study Team, Connie Celum, Jared M. Baeten, Deborah Donnell, Robert W. Coombs, Jairam R. Lingappa, M. Juliana McElrath, Kenneth H. Fife, Edwin Were, Elioda Tumwesigye, Patrick Ndase, Elly Katabira, Elly Katabira, Allan Ronald, Elizabeth A. Bukusi, Craig R. Cohen, Jonathan Wangisi, James D. Campbell, Jordan W. Tappero, James Kiarie, Carey Farquhar, Grace John‐Stewart, Nelly Mugo, Kenneth Ngure, James D. Campbell, Jordan W. Tappero, Jonathan Wangisi - Clinical Infectious Diseases 2020 被引用: 21

New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.